Roche - Big Pharma's Q2 2010 Earnings Report

FiercePharma says: Roche reported a 58 percent increase in first-half profit to $5.2 billion, helped by lower costs associated with the integration of Genentech. But the numbers fell short of expectations, and a drop in pharma sales of 2.3 percent had analysts moaning. "The results are not really that positive," Rahn & Bodmer's Birgit Kulhoff tells Bloomberg.

Roche's Q2 Highlights

  • Group first-half sales up 5% in local currencies (3% in Swiss francs, 7% in US dollars) to 24.6 billion Swiss francs.
  • Operating profit (before exceptional items) up significantly, rising 11% in local currencies (10% in Swiss francs) to 8.8 billion Swiss francs - again advancing faster than sales.
  • Net income rises 37% compared with first half of 2009; lower exceptional expenses relating to integration of Genentech.
  • Core earnings per share up 11% in local currencies, 9% in Swiss francs.
  • Full-year outlook for 2010 confirmed.

Roche's website: http://www.roche.com/
Full release: Roche earnings release

Roche - Big Pharma's Q2 2010 Earnings Report
Read more on

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.